HUGE vs. KZR, CASI, LEXX, KRON, NBRV, EGRX, AADI, CLNN, OCUP, and GANX
Should you be buying FSD Pharma stock or one of its competitors? The main competitors of FSD Pharma include Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Kronos Bio (KRON), Nabriva Therapeutics (NBRV), Eagle Pharmaceuticals (EGRX), Aadi Bioscience (AADI), Clene (CLNN), Ocuphire Pharma (OCUP), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical preparations" industry.
FSD Pharma (NASDAQ:HUGE) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking.
FSD Pharma has higher earnings, but lower revenue than Kezar Life Sciences. FSD Pharma is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
FSD Pharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
Kezar Life Sciences' return on equity of -47.28% beat FSD Pharma's return on equity.
In the previous week, FSD Pharma had 3 more articles in the media than Kezar Life Sciences. MarketBeat recorded 5 mentions for FSD Pharma and 2 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.94 beat FSD Pharma's score of 0.39 indicating that Kezar Life Sciences is being referred to more favorably in the news media.
Kezar Life Sciences has a consensus price target of $11.00, suggesting a potential upside of 1,485.01%. Given Kezar Life Sciences' higher possible upside, analysts clearly believe Kezar Life Sciences is more favorable than FSD Pharma.
Kezar Life Sciences received 134 more outperform votes than FSD Pharma when rated by MarketBeat users. Likewise, 58.01% of users gave Kezar Life Sciences an outperform vote while only 0.00% of users gave FSD Pharma an outperform vote.
1.2% of FSD Pharma shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 8.5% of FSD Pharma shares are held by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Kezar Life Sciences beats FSD Pharma on 11 of the 15 factors compared between the two stocks.
Get FSD Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FSD Pharma Competitors List
Related Companies and Tools
